Metis Global Partners, LLC Neurocrine Biosciences Inc Transaction History
Metis Global Partners, LLC
- $2.71 Billion
- Q1 2024
A detailed history of Metis Global Partners, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Metis Global Partners, LLC holds 2,211 shares of NBIX stock, worth $307,505. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,211
Previous 2,230
0.85%
Holding current value
$307,505
Previous $293,000
3.75%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.91 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.38 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$555 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$319 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$313 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...